Work

Loncastuximab Tesirine Shows Encouraging Results for the Treatment High-risk Follicular Lymphoma and Marginal Zone Lymphoma

Year: 2024

Type: article

Abstract: Updated results from the two studies with loncastuximab tesirine ((Zynlonta® ADC Therapeutics), a CD19-directed antibody-drug conjugate (ADC). were presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7 – 10, 2024, in San Diego, CA, and online. Both studies showed encouraging results in the treatment of patients diagnosed with high-risk forms of two blood cancers – follicular lymphoma (FL) and marginal zone lymphoma (MZL).

Source: ADC Review / Journal of Antibody-drug Conjugates

DOI: 10.14229/jadc.2024.12.13.002

Author: Danielle Garcia

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4405900039

FWCI:

Cites: 3

Cited by:

Related to: 10